Wei Xiunan, Leng Xiaohui, Li Gongyi, Wang Ruting, Chi Lili, Sun Dajuan
College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Weifang Traditional Chinese Hospital, Weifang, China.
Front Pharmacol. 2023 Feb 23;14:1120672. doi: 10.3389/fphar.2023.1120672. eCollection 2023.
Inflammatory bowel disease (IBD) can progress into colitis-associated colorectal cancer (CAC) through the inflammation-cancer sequence. Although the mechanism of carcinogenesis in IBD has not been fully elucidated, the existing research indicates that CAC may represent a fundamentally different pathogenesis pattern of colorectal cancer. At present, there is no proven safe and effective medication to prevent IBD cancer. In recent years, Chinese medicine extracts and Chinese medicine monomers have been the subject of numerous articles about the prevention and treatment of CAC, but their clinical application is still relatively limited. Traditional Chinese Medicine (TCM) formulas are widely applied in clinical practice. TCM formulas have demonstrated great potential in the prevention and treatment of CAC in recent years, although there is still a lack of review. Our work aimed to summarize the effects and potential mechanisms of TCM formulas for the prevention and treatment of CAC, point out the issues and limitations of the current research, and provide recommendations for the advancement of CAC research in the future. We discovered that TCM formulas regulated many malignant biological processes, such as inflammation-mediated oxidative stress, apoptosis, tumor microenvironment, and intestinal microecology imbalance in CAC, through a review of the articles published in databases such as . Several major signal transduction pathways, including NF-κB, STAT3, Wnt/β-catenin, HIF-1α, and Nrf2, were engaged. TCM formula may be a promising treatment candidate to control the colitis-cancer transformation, however further high-quality research is required.
炎症性肠病(IBD)可通过炎症 - 癌症序列进展为结肠炎相关结直肠癌(CAC)。尽管IBD的致癌机制尚未完全阐明,但现有研究表明,CAC可能代表一种与结直肠癌根本不同的发病机制模式。目前,尚无经证实安全有效的预防IBD相关癌症的药物。近年来,中药提取物和中药单体一直是众多关于CAC防治文章的主题,但其临床应用仍然相对有限。中药方剂在临床实践中广泛应用。近年来,中药方剂在CAC的防治方面已显示出巨大潜力,尽管仍缺乏综述。我们的工作旨在总结中药方剂防治CAC的作用及潜在机制,指出当前研究存在的问题和局限性,并为未来CAC研究的推进提供建议。通过对诸如……等数据库中发表的文章进行综述,我们发现中药方剂可调节许多恶性生物学过程,如炎症介导的氧化应激、细胞凋亡、肿瘤微环境以及CAC中的肠道微生态失衡。涉及了包括NF - κB、STAT3、Wnt/β - 连环蛋白、HIF - 1α和Nrf2在内的几个主要信号转导通路。中药方剂可能是控制结肠炎 - 癌症转化的一种有前景的治疗选择,然而还需要进一步的高质量研究。